ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Is Down 5.0% After New Approvals Expand Its Rare Disease Portfolio - Has The Bull Case Changed?
In mid-January 2026, China’s National Medical Products Administration approved Sanofi-licensed Myqorzo and Redemplo, while the EU cleared Teizeild to delay stage 3 type 1 diabetes, expanding access to innovative therapies across cardiology, rare lipid disorders, and autoimmune disease.
These approvals highlight Sanofi’s growing role in bringing disease-modifying and first-in-class treatments to patients with severe, inherited, and hard-to-treat conditions across major global markets.
Next,...